Adjuvant treatment of postmenopausal estrogen receptor-α (ER)+ breast cancer involves reducing estrogen secretion through endocrine-targeting therapies such as selective estrogen receptor modulators (SERM). Here, ESR1 is linked to breast carcinoma.